A recent report using colitis associated carcinoma model showed that CD73 promoted tumor development as evidenced by reduced tumor burden in mice after treating with an CD73 pharmacologic inhibitor, APCP, supporting an oncogenic role for CD73 in mouse tumorigenesis (36). The gene discussed is NT5E; the disease is neoplasm.